DE602004030541D1 - Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen - Google Patents
Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexenInfo
- Publication number
- DE602004030541D1 DE602004030541D1 DE200460030541 DE602004030541T DE602004030541D1 DE 602004030541 D1 DE602004030541 D1 DE 602004030541D1 DE 200460030541 DE200460030541 DE 200460030541 DE 602004030541 T DE602004030541 T DE 602004030541T DE 602004030541 D1 DE602004030541 D1 DE 602004030541D1
- Authority
- DE
- Germany
- Prior art keywords
- macroglobulin
- complexes
- molecular complexes
- alpha
- preparing alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 210000002966 serum Anatomy 0.000 abstract 3
- 208000035473 Communicable disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44902203P | 2003-02-20 | 2003-02-20 | |
US45075103P | 2003-02-27 | 2003-02-27 | |
PCT/US2004/005110 WO2004074454A2 (en) | 2003-02-20 | 2004-02-20 | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004030541D1 true DE602004030541D1 (de) | 2011-01-27 |
Family
ID=32912315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200460030541 Expired - Lifetime DE602004030541D1 (de) | 2003-02-20 | 2004-02-20 | Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen |
Country Status (8)
Country | Link |
---|---|
US (2) | US8877204B2 (de) |
EP (1) | EP1601756B1 (de) |
JP (1) | JP4976848B2 (de) |
AT (1) | ATE491463T1 (de) |
AU (1) | AU2004213855B2 (de) |
DE (1) | DE602004030541D1 (de) |
ES (1) | ES2385933T3 (de) |
WO (1) | WO2004074454A2 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7449557B2 (en) | 2000-06-02 | 2008-11-11 | University Of Connecticut Health Center | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
ES2385933T3 (es) | 2003-02-20 | 2012-08-03 | University Of Connecticut Health Center | Métodos para la producción de complejos de moléculas antígenas de alfa (2) macroglobulina. |
WO2008021981A2 (en) * | 2006-08-09 | 2008-02-21 | Nexgenix Pharmaceuticals, Llc. | Local treatment of epidermal and dermal hyperproliferative lesions |
EP2227147A1 (de) * | 2007-11-21 | 2010-09-15 | Focus Surgery, Inc. | Verfahren zur diagnose und behandlung von tumoren mit fokussiertem hochintensitäts-ultraschall |
US20090181931A1 (en) * | 2008-01-16 | 2009-07-16 | Oncolys Biopharma, Inc. | Antiviral activity of cidofovir against oncolytic viruses |
DK2257301T3 (da) | 2008-03-03 | 2014-04-28 | Univ Miami | Immunterapi baseret på allogene cancerceller. |
AU2013222414B2 (en) * | 2012-02-21 | 2018-02-15 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
WO2015031654A2 (en) * | 2013-08-28 | 2015-03-05 | Cytonics Corporation | Systems, compositions, and methods for transplantation and treating conditions |
US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
US10889631B2 (en) | 2014-11-20 | 2021-01-12 | Cytonics Corporation | Therapeutic variant alpha-2-macroglobulin compositions |
CA2984643A1 (en) | 2015-05-13 | 2016-11-17 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
CA3096909A1 (en) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
WO2020018888A1 (en) | 2018-07-20 | 2020-01-23 | The Board Of Regents Of The University Of Oklahoma | Antimicrobial peptides and methods of use |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5231674B1 (de) | 1969-03-29 | 1977-08-16 | ||
US4392040A (en) | 1981-01-09 | 1983-07-05 | Rand Robert W | Induction heating apparatus for use in causing necrosis of neoplasm |
US4545368A (en) | 1983-04-13 | 1985-10-08 | Rand Robert W | Induction heating method for use in causing necrosis of neoplasm |
WO1985002779A1 (en) | 1983-12-27 | 1985-07-04 | Board Of Trustees Of Leland Stanford Junior Univer | Catheter for treatment of tumors and method for using same |
US4983159A (en) | 1985-03-25 | 1991-01-08 | Rand Robert W | Inductive heating process for use in causing necrosis of neoplasms at selective frequencies |
US5149527A (en) | 1990-09-18 | 1992-09-22 | Oncotech, Inc. | Immunopotentiating protocol for chemotherapy-responsive tumors |
AU5873994A (en) | 1992-12-18 | 1994-07-19 | Duke University | Immune response modulator complex, and uses thereof |
US5750119A (en) | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US6194388B1 (en) | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO1997004794A1 (en) | 1995-07-27 | 1997-02-13 | The American National Red Cross | Modulators of expression and function of lrp in alzheimer's disease |
US6156311A (en) | 1995-07-27 | 2000-12-05 | The American National Red Cross | Modulators of expression and function of LRP in alzheimer's disease |
CA2231998A1 (en) | 1995-09-13 | 1997-03-20 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US5985270A (en) | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US5747332A (en) | 1996-09-20 | 1998-05-05 | University Of New Mexico | Methods for purifying and synthesizing heat shock protein complexes |
US5947646A (en) * | 1997-02-25 | 1999-09-07 | Guardian Fiberglass, Inc. | System for blowing loose-fill insulation |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
JP5087758B2 (ja) | 1997-03-10 | 2012-12-05 | オタワ ホスピタル リサーチ インスティチュート | アジュバントとして非メチル化CpGジヌクレオチドを含む核酸の使用 |
DE69838294T2 (de) | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
EP0986572B2 (de) | 1997-06-06 | 2007-06-13 | Dynavax Technologies Corporation | Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon |
CA2312049A1 (en) | 1997-12-05 | 1999-06-17 | The University Of New Mexico | Method for purifying heat shock peptides complexes |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
US6403092B1 (en) | 1998-04-01 | 2002-06-11 | Duke University | Immune response modulator alpha-2 macroglobulin complex |
ATE356630T1 (de) | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
SI1077722T1 (sl) | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Metode in produkti za induciranje sluznicne imunosti |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
AU764532B2 (en) | 1998-07-27 | 2003-08-21 | University Of Iowa Research Foundation, The | Stereoisomers of CpG oligonucleotides and related methods |
EP2314693A3 (de) | 1999-08-13 | 2012-11-28 | Idera Pharmaceuticals, Inc. | Modulierung der durch CpG-oligonukleotide verursachte Immunstimulierung durch positionsbedingte Veränderung von Nukleosiden |
ATE419869T1 (de) | 1999-08-19 | 2009-01-15 | Dynavax Tech Corp | Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür |
EE200200158A (et) | 1999-09-25 | 2003-06-16 | University Of Iowa Research Foundation | Immunostimulatoorsed nukleiinhapped |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
JP2003527352A (ja) | 2000-01-13 | 2003-09-16 | アンティジェニクス インコーポレーテッド | Cpgおよびサポニンの自然免疫刺激化合物、ならびにそれらの方法 |
CA2396871A1 (en) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
ATE382690T1 (de) | 2000-01-26 | 2008-01-15 | Idera Pharmaceuticals Inc | Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden |
EP1278761B1 (de) | 2000-05-01 | 2005-04-06 | Hybridon, Inc. | Modulation von oligonukleotid cpg-vermittelter immunstimulation durch modifikation der nucleoside |
US7179462B2 (en) | 2000-06-02 | 2007-02-20 | University Of Connecticut Health Center | α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof |
US7449557B2 (en) | 2000-06-02 | 2008-11-11 | University Of Connecticut Health Center | Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
EP1322747A4 (de) | 2000-09-15 | 2004-12-29 | Univ Connecticut Health Ct | Verbesserte formulierungen durch verwendung von hitzeschock-/stress-protein-peptid-komplexen |
EP1322656B1 (de) | 2000-09-26 | 2008-01-16 | Idera Pharmaceuticals, Inc. | Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen |
CA2430691A1 (en) | 2000-12-27 | 2002-07-04 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
WO2003015712A2 (en) | 2001-08-20 | 2003-02-27 | University Of Connecticut Health Center | Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin |
US6984389B2 (en) * | 2002-04-25 | 2006-01-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
WO2003090686A2 (en) * | 2002-04-25 | 2003-11-06 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
CA2483925A1 (en) | 2002-05-02 | 2004-04-29 | University Of Connecticut Health Center | Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines comprising heat shock protein-peptide complexes or alpha-2-macroglobulin-peptide complexes |
ES2385933T3 (es) | 2003-02-20 | 2012-08-03 | University Of Connecticut Health Center | Métodos para la producción de complejos de moléculas antígenas de alfa (2) macroglobulina. |
AU2003223226A1 (en) | 2003-02-20 | 2004-09-17 | University Of Connecticut Health Center | Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease |
WO2004078921A2 (en) | 2003-02-27 | 2004-09-16 | University Of Connecticut Health Center | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes |
WO2005120558A2 (en) | 2004-05-25 | 2005-12-22 | University Of Connecticut Health Center | Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease |
BRPI0909096A2 (pt) | 2008-03-05 | 2015-12-01 | Cytos Biotechnology Ag | uso de conjugados de interleicna-1 no tratamento de diabetes |
-
2004
- 2004-02-20 ES ES04713422T patent/ES2385933T3/es not_active Expired - Lifetime
- 2004-02-20 AU AU2004213855A patent/AU2004213855B2/en not_active Ceased
- 2004-02-20 US US10/546,106 patent/US8877204B2/en not_active Expired - Fee Related
- 2004-02-20 DE DE200460030541 patent/DE602004030541D1/de not_active Expired - Lifetime
- 2004-02-20 EP EP20040713422 patent/EP1601756B1/de not_active Expired - Lifetime
- 2004-02-20 AT AT04713422T patent/ATE491463T1/de not_active IP Right Cessation
- 2004-02-20 JP JP2006503751A patent/JP4976848B2/ja not_active Expired - Fee Related
- 2004-02-20 WO PCT/US2004/005110 patent/WO2004074454A2/en active Application Filing
-
2014
- 2014-09-26 US US14/498,419 patent/US9566348B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2004074454A2 (en) | 2004-09-02 |
ATE491463T1 (de) | 2011-01-15 |
EP1601756A2 (de) | 2005-12-07 |
WO2004074454A3 (en) | 2006-12-07 |
US20060165710A1 (en) | 2006-07-27 |
JP4976848B2 (ja) | 2012-07-18 |
AU2004213855A1 (en) | 2004-09-02 |
US20150118253A1 (en) | 2015-04-30 |
US8877204B2 (en) | 2014-11-04 |
EP1601756A4 (de) | 2007-10-24 |
JP2007524580A (ja) | 2007-08-30 |
ES2385933T3 (es) | 2012-08-03 |
US9566348B2 (en) | 2017-02-14 |
EP1601756B1 (de) | 2010-12-15 |
AU2004213855B2 (en) | 2010-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60225666D1 (de) | Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung | |
CY1108009T1 (el) | Αποτελεσματικα πεπτιδια στη θεραπεια ογκων ή αλλων ασθενειων που απαιτουν την εξαιρεση ή καταστροφη κυτταρων | |
DE602004030541D1 (de) | Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen | |
YU46097A (sh) | Nova klasa estara i njihove farmaceutske smeše | |
ATE429442T1 (de) | Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie | |
CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
DE60204322D1 (de) | Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen | |
CY1107146T1 (el) | Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad) | |
DE60114002D1 (de) | VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION | |
CY1112055T1 (el) | Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα | |
ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
EP1362127A4 (de) | Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung | |
DE60021381D1 (de) | Chinonverbindungen zur behandlung von krankheiten | |
DE502005000428D1 (de) | Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen | |
DE60129518D1 (de) | Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension | |
EP1423414A4 (de) | Neue depsipeptide und verfahren zu deren herstellung | |
ATE372336T1 (de) | Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen | |
ATE213163T1 (de) | Verfahren zur behandlung von motorischen defiziten | |
DE602004021363D1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
DE602004030661D1 (de) | Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis | |
WO2004078921A3 (en) | Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes | |
ATE460168T1 (de) | Nicht-radioaktives strontiummittel zur behandlung von krebs | |
WO2005054204A3 (en) | Pharmaceutical compounds that regenerate in vivo |